{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T22:05:32Z","timestamp":1761602732834,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2023.03.012","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T09:40:23Z","timestamp":1679391623000},"page":"587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regarding the article entitled \u201cEffect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis\u201d"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-3783","authenticated-orcid":false,"given":"Zhe Hui","family":"Hoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana YH","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-9921","authenticated-orcid":false,"given":"Robert D","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-8898","authenticated-orcid":false,"given":"Tracey E","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-3215","authenticated-orcid":false,"given":"Sophie","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4710-657X","authenticated-orcid":false,"given":"Marlene","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J","family":"Wildman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.03.012_bib0001","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","author":"Lee","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.03.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(22)00739-1","article-title":"Clinical outcomes of adults and children with cystic fibrosis during the Covid-19 pandemic","author":"Doumit","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.03.012_bib0003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2021.08.013","article-title":"A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis","volume":"21","author":"Paynter","year":"2022","journal-title":"J Cyst Fibros"},{"unstructured":"Centers for Disease Control and Prevention. CDC museum Covid-19 timeline. Published August 2022. https:\/\/www.cdc.gov\/museum\/timeline\/covid19.html#:\u223c:text=March%2015%2C%202020,the%20spread%20of%20COVID%2D19. Date last accessed: March 8 2023.","key":"10.1016\/j.jcf.2023.03.012_bib0004"},{"key":"10.1016\/j.jcf.2023.03.012_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/aje\/kwab263","article-title":"Using negative control outcomes and difference-in-differences analysis to estimate treatment effects in an entirely treated cohort: the effect of ivacaftor in cystic fibrosis","volume":"191","author":"Newsome","year":"2022","journal-title":"Am J Epidemiol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:45Z","timestamp":1761601665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199323000760"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"type":"print","value":"1569-1993"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regarding the article entitled \u201cEffect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}